Consensus Pfizer, Inc.

Equities

PFE

US7170811035

Real-time Estimate Cboe BZX Other stock markets 10:37:23 2024-04-19 am EDT			5-day change	1st Jan Change
25.58 ^USD	+0.77%		-1.28%	-11.32%

Apr. 17	Sector Update: Health Care Stocks Retreating Late Afternoon	MT
Apr. 17	Sector Update: Health Care	MT

Evolution of the average Target Price on Pfizer, Inc.

Price target over the last 5 years

History of analyst recommendation changes

7762f591d7789a5ecc12d.FKtPQM-1p1caBNQ6ghPYgxXVi-Z62i5jSAgdL0-MXlY.YuModqT94gZsZoN80HGq-3y6v6IXmGIuADhlAhfYH2V_niERlozBDkBG7A~e40a430f02eadfedbd92552e67ebb4fa

Analyst Recommendations on Pfizer, Inc.

Connect Biopharma Terminates Agreement on Antiallergic Candidate With Pfizer	Apr. 17	MT
Novavax Shareholder Shah Capital Pushes to Add 2 Nominees to Company's Board	Apr. 15	MT
PFIZER INC : JP Morgan remains Neutral	Apr. 12	ZD
Skanska Trims Scope of Work for Biomanufacturing Facility Project in US	Apr. 12	MT
PFIZER INC : Berenberg remains Neutral	Apr. 10	ZD
Argus Downgrades Pfizer to Hold From Buy	Mar. 22	MT
PFIZER INC : JP Morgan sticks Neutral	Mar. 07	ZD
PFIZER INC : JP Morgan sticks Neutral	Mar. 01	ZD
Guggenheim Initiates Pfizer With Buy Rating, Price Target is $36	Feb. 23	MT
China move leaves markets unfazed	Feb. 20
Indian shares set to open higher ahead of national budget	Jan. 31	RE
UBS Trims Pfizer Price Target to $28 From $29, Maintains Neutral Rating	Jan. 31	MT
PFIZER INC : UBS gives a Neutral rating	Jan. 31	ZD
PFIZER INC : Buy rating from Jefferies	Jan. 30	ZD
PFIZER INC : DZ Bank maintains a Buy rating	Jan. 30	ZD
PFIZER INC : JP Morgan gives a Neutral rating	Jan. 30	ZD
PFIZER INC : UBS reaffirms its Neutral rating	Jan. 30	ZD
PFIZER INC : JP Morgan remains Neutral	Jan. 30	ZD
PFIZER INC : Berenberg gives a Neutral rating	Jan. 25	ZD
PFIZER INC : Gets a Neutral rating from JP Morgan	Jan. 22	ZD
UBS Adjusts Pfizer Price Target to $29 From $27, Maintains Neutral Rating	Jan. 17	MT
WHO sees 'incredibly low' COVID, flu vaccination rates as cases surge	Jan. 12	RE
Nvidia comes to Wall Street's rescue	Jan. 09
Berenberg: M&A Dealmaking in Pharmaceutical Sector to Further Accelerate in 2024	Jan. 09	MT
TD Cowen Downgrades Pfizer to Market Perform From Outperform, Price Target is $32	Jan. 04	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

25.39 USD

Average target price

31.62 USD

Spread / Average Target

+24.54%

High Price Target

45 USD

Spread / Highest target

+77.24%

Low Price Target

26 USD

Spread / Lowest Target

+2.40%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Pfizer, Inc.

JPMORGAN	Chris Schott
BERENBERG	Kerry Holford
Argus
Guggenheim
UBS
DZ BANK	Elmar Kraus
JEFFERIES	Akash Tewari
TD Cowen
Morgan Stanley
Cantor Fitzgerald
Truist Securities
Daiwa Securities
Wells Fargo Securities
Redburn
JPMorgan Chase
Barclays
Jefferies & Co.
Goldman Sachs
Credit Suisse
SVB Securities LLC
BMO Capital
HSBC
Berenberg Bank
BofA Securities
Atlantic Equities
Citigroup
Mizuho Securities
Atlantic Securities
SVB Leerink
Independent Research
RBC
RBC Capital Markets
J.P. Morgan Chase

Ratings for Pfizer, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar